相关实验视频

Updated: May 5, 2026

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

质母细胞瘤的低分离放射治疗:与预后因素和生存结果的相关性

Dimcho Georgiev¹, Svetlana Bilyukova¹, Cyril Kounin²

¹University Specialized Hospital for Active Treatment of Oncology "Prof. Ivan Tzernozemski", Sofia, Bulgaria.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

|January 8, 2026

概括

用temozolomide (TMZ) 进行常规分离放射治疗 (CFRT) 之后的低分离放射治疗 (HFRT) 在多种质母细胞瘤 (GBM) 患者中显示出有效性. 生存的关键预后因素包括患者年龄和总瘤体积 (GTV).

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
神经瘤学神经瘤学

背景情况:

多型质母细胞瘤 (GBM) 在神经瘤学中是一个重大挑战.
标准治疗通常涉及常规分离放射治疗 (CFRT).
评估新的放射治疗计划对于改善患者的治疗结果至关重要.

研究的目的:

在GBM患者中评估联合低分离放射治疗 (HFRT) 和CFRT疗程的疗效.
在这个患者队列中确定影响整体生存 (OS) 的显著预后因素.

主要方法:

在2010年至2017年期间接受治疗的120名GBM患者的回顾性分析.
患者接受了术后的HFRT (30 Gy/3 Gy),然后是CFRT (24 Gy/2 Gy),总共60 Gy.
所有参与者都接受了并发和辅助的temozolomide (TMZ).

主要成果:

平均整体存活时间 (OS) 为11.3个月,1年,2年和3年生存率分别为43.3%,16.1%和4.6%.
完整的放射治疗剂量交付与改善的OS相关.
年龄较小 (≤63岁) 和总瘤体积较小 (GTV ≤44.5厘米3) 与更好的生存结果有显著的关联.

结论:

HFRT和CFRT与TMZ的结合为GBM患者提供了有效的治疗替代方案,特别是那些部分或部分切除的患者.
患者年龄和GTV被确定为影响GBM总生存的独立预后因素.
这种治疗策略在质母细胞瘤的治疗中值得考虑.

关键词:

大脑瘤是个大脑瘤质母细胞瘤是一种质母细胞瘤.低分离辐射疗法低分离辐射疗法预后因素预后因素

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...